Literature DB >> 15282675

Desferrioxamine related maculopathy: a case report.

Anita Arora1, Siobhan Wren, Kevin Gregory Evans.   

Abstract

Desferrioxamine is used for the treatment of chronic iron overload, acute iron poisoning, and certain anaemias. Ocular toxicity secondary to prolonged treatment with desferrioxamine may result in night blindness, visual field constriction, cataract, pigmentary retinopathy and optic neuropathy. To avoid such complications an ophthalmic screening has been suggested for patients taking desferrioxamine. We report an 81-year-old patient who developed irreversible ocular toxicity despite undergoing ophthalmic screening. Copyright 2004 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15282675     DOI: 10.1002/ajh.20090

Source DB:  PubMed          Journal:  Am J Hematol        ISSN: 0361-8609            Impact factor:   10.047


  9 in total

1.  Rapid development of severe toxic retinopathy associated with continuous intravenous deferoxamine infusion.

Authors:  T Y Y Lai; G K Y Lee; W-M Chan; D S C Lam
Journal:  Br J Ophthalmol       Date:  2006-02       Impact factor: 4.638

Review 2.  Ocular abnormalities in beta thalassemia patients: prevalence, impact, and management strategies.

Authors:  Samira Heydarian; Reza Jafari; Kiumars Nowroozpoor Dailami; Hassan Hashemi; Ebrahim Jafarzadehpour; Mohsen Heirani; Abbasali Yekta; Monireh Mahjoob; Mehdi Khabazkhoob
Journal:  Int Ophthalmol       Date:  2019-10-10       Impact factor: 2.031

Review 3.  Oral nucleic acid therapy using multicompartmental delivery systems.

Authors:  Husain Attarwala; Murui Han; Jonghan Kim; Mansoor Amiji
Journal:  Wiley Interdiscip Rev Nanomed Nanobiotechnol       Date:  2017-05-24

4.  Desferrioxamine-related ocular toxicity: a case report.

Authors:  Sumu Simon; Paul A Athanasiov; Rajeev Jain; Grant Raymond; Jagjit S Gilhotra
Journal:  Indian J Ophthalmol       Date:  2012-07       Impact factor: 1.848

Review 5.  Functional and Structural Abnormalities in Deferoxamine Retinopathy: A Review of the Literature.

Authors:  Maura Di Nicola; Giulio Barteselli; Laura Dell'Arti; Roberto Ratiglia; Francesco Viola
Journal:  Biomed Res Int       Date:  2015-06-08       Impact factor: 3.411

6.  Deferoxamine retinopathy: spectral domain-optical coherence tomography findings.

Authors:  Cheng-Hsiu Wu; Chao-Ping Yang; Chi-Chun Lai; Wei-Chi Wu; Yi-Hsing Chen
Journal:  BMC Ophthalmol       Date:  2014-07-02       Impact factor: 2.209

7.  Renal clearable nanochelators for iron overload therapy.

Authors:  Homan Kang; Murui Han; Jie Xue; Yoonji Baek; JuOae Chang; Shuang Hu; HaYoung Nam; Min Joo Jo; Georges El Fakhri; Michael P Hutchens; Hak Soo Choi; Jonghan Kim
Journal:  Nat Commun       Date:  2019-11-13       Impact factor: 14.919

8.  Pattern dystrophies in patients treated with deferoxamine: report of two cases and review of the literature.

Authors:  Constantine D Georgakopoulos; Foteini Tsapardoni; Elli V Kostopoulou; Olga E Makri
Journal:  BMC Ophthalmol       Date:  2018-09-12       Impact factor: 2.209

Review 9.  From Rust to Quantum Biology: The Role of Iron in Retina Physiopathology.

Authors:  Emilie Picard; Alejandra Daruich; Jenny Youale; Yves Courtois; Francine Behar-Cohen
Journal:  Cells       Date:  2020-03-13       Impact factor: 6.600

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.